BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 1, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Inxmed to use Escugen’s Ezwi-Fit linker-payload platform in development of antibody-drug conjugates
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
Inxmed to use Escugen’s Ezwi-Fit linker-payload platform in development of antibody-drug conjugates
Dec. 20, 2023
No Comments
Inxmed Co. Ltd. has licensed Escugen’s Ezwi-Fit linker-payload platform for use in the development of next-generation tumor-associated antigen (TAA)-targeting antibody-drug conjugates (ADCs).
BioWorld Science
Cancer
Antibody-drug conjugate
Immuno-oncology